Study guide
5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers
Key Takeaways Explain This Topic AI
Pancreatic ductal adenocarcinoma and Whipple procedures induce Pancreatic Exocrine Insufficiency (PEI), requiring Pancreatic Enzyme Replacement Therapy (PERT) starting at 40,000-50,000 lipase units per main meal.
PERT capsules contain enteric-coated microspheres that must be ingested with the first bites of meals and snacks; co-administration of a proton pump inhibitor (PPI) enhances PERT efficacy by preventing duodenal acid inactivation.
High-output ileostomies (>1,000-1,500 mL/day post-colectomy) risk severe dehydration and hyponatremia; management requires hypertonic Oral Rehydration Solutions (ORS) with sodium (75-90 mEq/L) while restricting free water, hypotonic, and hypertonic simple sugar fluids.
Terminal ileal resection with an intact colon increases enterogenous calcium oxalate kidney stone risk due to fatty acid binding of luminal calcium; management requires low-oxalate diet and dietary calcium supplementation with meals.
Last updated: August 2026
5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers
Quick Summary: Abdominal and pelvic malignancies demand specialized management of digestive enzyme kinetics, fluid-electrolyte balance post-intestinal resection, and intra-abdominal volume pressures. Pancreatic Exocrine Insufficiency (PEI) requires PERT dosing starting at 40,000–50,000 lipase units per meal. High-output ileostomies (>1,000–1,500 mL/day) require restricting hypotonic free water and prescribing high-sodium Oral Rehydration Solutions (ORS). Ovarian cancer with malignant ascites requires sodium restriction (≤2,000 mg/day) and small nutrient-dense meals.
1. Pancreatic Cancer MNT & PERT Optimization
Pancreatic head adenocarcinoma, biliary duct obstruction, and surgical resection ( Pancreaticoduodenectomy / Whipple procedure ) lead to profound Pancreatic Exocrine Insufficiency (PEI) , resulting in severe fat malabsorption, steatorrhea, weight loss, and fat-soluble vitamin (A, D, E, K) deficiencies.
Pancreatic Enzyme Replacement Therapy (PERT) Dosing Protocol
Initial Starting Dose : 40,000 to 50,000 USP lipase units per main meal , and 20,000 to 25,000 units per snack .
Dose Titration : Increase up to a maximum cap of 10,000 lipase units/kg/day or <2,500 lipase units/kg/meal based on stool frequency, consistency, and resolution of steatorrhea.
Administration Timing : Capsules must be swallowed with the first bites of food (or split throughout the meal). Never crush or chew enteric-coated microspheres.
Gastric Acid Suppression : If steatorrhea persists despite adequate PERT dosing, add a Proton Pump Inhibitor (PPI) or H 2 H_2 H 2 -receptor antagonist. Gastric hypersecretion inactivates exogenous lipase, which denatures at a p H < 5.5 pH < 5.5 p H < 5.5 .
Pancreatogenic (Type 3c) Diabetes Mellitus : Whipple resections reduce islet cell mass, inducing Type 3c DM. Type 3c DM features concurrent loss of insulin (beta cells) and glucagon (alpha cells), causing severe glycemic volatility and brittle hypoglycemia. MNT requires consistent carbohydrate distribution and high protein intake.
2. Colorectal Cancer & Ostomy Fluid Management
Surgical resections for colorectal carcinoma include right/left hemicolectomy, low anterior resection (LAR), or total abdominal colectomy with creation of an ileostomy or colostomy .
High-Output Ileostomy Protocol (>1,000 – 1,500 mL/day)
Ileostomies bypass the colon, eliminating its 1.5 L/day fluid and sodium absorptive capacity. Fresh ileostomies lose large amounts of sodium (100–140 mEq/L) and water.
Parameter Clinical Protocol & Dietary Intervention
Fluid Selection RESTRICT free water, tea, coffee, plain tap water, and sodas (hypotonic fluids draw sodium into bowel lumen via osmosis, worsening output). Prescribe Oral Rehydration Solutions (ORS) containing 75–90 mEq/L Sodium and glucose to activate intestinal SGLT-1 co-transporters.
Dietary Sodium Increase dietary salt intake (add 1–2 tsp table salt daily to food, salty broths, pretzels).
Thickeners Incorporate soluble fiber thickeners: bananas, applesauce, smooth peanut butter, oatmeal, boiled rice, pectin.
Entero-Oxalate Nephrolithiasis Patients with terminal ileal resections who retain an intact colon must restrict high-oxalate foods (spinach, nuts, chocolate, tea). Unabsorbed fatty acids bind luminal calcium (saponification), leaving free oxalate to be hyper-absorbed in the colon, causing calcium oxalate kidney stones . Treat with low-oxalate diet and oral Calcium Carbonate/Citrate supplements given with meals to bind oxalate in the gut.
3. Gynecologic Cancers MNT (Ovarian, Uterine, Cervical)
Advanced epithelial ovarian cancer frequently metastasizes across the peritoneum (peritoneal carcinomatosis), presenting with malignant ascites , severe early satiety, nausea, and high risk for Malignant Bowel Obstruction (MBO) .
Malignant Ascites & MBO Protocols
Sodium Restriction : Limit dietary sodium to ≤2,000 mg/day to reduce fluid retention rate.
Small, Nutrient-Dense Meals : Ascitic fluid accumulation elevates intra-abdominal pressure, compressing the stomach. Implement 6 to 8 small, high-calorie, high-protein meals daily.
Malignant Bowel Obstruction (MBO) : In inoperable MBO, transition to a low-residue/minimal-fiber soft diet or clear liquids. If complete obstruction occurs, place NPO, initiate venting gastrostomy, and evaluate for TPN if prognosis >2–3 months.
- Worked Case Example: High-Output Ileostomy Management
- Patient Scenario
A 50-year-old male post-colectomy with a new end-ileostomy presents with 2,400 mL/day stoma output, serum sodium of 130 mEq/L, and dry mucous membranes. He has been drinking 3 liters of plain tap water and iced tea daily.
Diagnostic & Clinical Nutrition Assessment
Primary Issue : High-output ileostomy exacerbated by large hypotonic fluid ingestion (tap water/tea), driving osmotic sodium movement into the intestinal lumen.
MNT Prescribed :
Restrict tap water, tea, and hypotonic fluids to <500 mL/day.
Initiate WHO-formula Oral Rehydration Solution (ORS) containing 75 mEq/L sodium at 1,500 mL/day.
Add 1 tsp table salt to solid meals daily.
Add soluble fiber (pectin/oat bran) to solidify stool consistency.
Initiate anti-motility therapy (loperamide 2–4 mg prior to meals).